Drug and Therapeutics Bulletin 1996;34:49-52; doi:10.1136/dtb.1996.34749
Copyright © 1996 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

Too many beta-blockers

Relevant BNF section: 2.4

Fifteen beta-blockers are marketed in the UK for systemic use. For their main indications alone - the treatment of hypertension and angina pectoris - over 70 differently named generic and proprietary products exist, often in several formulations, some combined with a diuretic or calcium antagonist. In this article, we discuss the use of beta-blockers generally and consider which are required to meet clinical needs.






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 1996 BMJ Publishing Group Ltd.